Lantheus Holdings, Inc. $LNTH Holdings Trimmed by BI Asset Management Fondsmaeglerselskab A S

Key Points

• BI Asset Management Fondsmaeglerselskab A S reduced its holdings in Lantheus Holdings, Inc. by 66.1% during the first quarter, selling 65,460 shares and leaving them with 33,600 shares valued at approximately $3.28 million.
• Director Mary Anne Heino sold 26,066 shares of Lantheus for about $2.00 million, representing a 7.56% decrease in her ownership.
• Lantheus reported earnings of $1.57 per share for the last quarter, missing expectations and showing a 4.1% decline in revenue year-over-year.

BI Asset Management Fondsmaeglerselskab A S cut its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 66.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 33,600 shares of the medical equipment provider's stock after selling 65,460 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in Lantheus were worth $3,279,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Signaturefd LLC lifted its stake in Lantheus by 36.5% during the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 116 shares during the last quarter. Hughes Financial Services LLC bought a new position in Lantheus during the first quarter worth $81,000. UMB Bank n.a. lifted its stake in Lantheus by 68.2% during the first quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock worth $92,000 after purchasing an additional 381 shares during the last quarter. Blue Trust Inc. lifted its stake in Lantheus by 117.7% during the first quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock worth $114,000 after purchasing an additional 633 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in Lantheus by 29.3% during the first quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider's stock worth $128,000 after purchasing an additional 298 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Insider Activity at Lantheus

In related news, insider Rajiv A. Patel sold 3,365,000 shares of the firm's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares of the company's stock, valued at $195,246,296.05. This trade represents a 49.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mary Anne Heino sold 26,066 shares of the firm's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the transaction, the director directly owned 318,650 shares of the company's stock, valued at $24,481,879.50. This represents a 7.56% decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,838,066 shares of company stock valued at $384,430,031 over the last 90 days. 1.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on LNTH. Truist Financial set a $63.00 price objective on Lantheus and gave the company a "hold" rating in a research report on Monday, August 11th. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. B. Riley reduced their price objective on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research report on Monday, June 23rd. Mizuho reduced their price objective on Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, August 7th. Finally, William Blair restated a "market perform" rating on shares of Lantheus in a research report on Wednesday, July 16th. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $105.50.

Lantheus Stock Performance

Shares of NASDAQ:LNTH traded down $1.9690 on Monday, hitting $56.2410. The company's stock had a trading volume of 689,674 shares, compared to its average volume of 1,209,156. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $118.21. The company has a market capitalization of $3.82 billion, a price-to-earnings ratio of 14.97 and a beta of 0.14. The stock's 50-day moving average is $71.48 and its two-hundred day moving average is $84.19. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.08). The business had revenue of $378.05 million during the quarter, compared to the consensus estimate of $389.69 million. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The company's revenue for the quarter was down 4.1% compared to the same quarter last year. During the same period in the previous year, the company posted $1.80 EPS. On average, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.